Healthy
Conditions
Brief summary
The study is a Phase I, randomized, double-blind, placebo-controlled study evaluating multiple ascending oral doses of GLPG2451 and the combination of GLPG2451 and GLPG2222 given for 14 days in healthy male subjects. The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses of GLPG2451 given to healthy male subjects compared to placebo, as well as of multiple oral doses of the combination of GLPG2451/GLPG2222 compared to placebo.
Interventions
DRUGGLPG2451 multiple dose
GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
Placebo, oral suspension, daily for 14 days
DRUGGLPG2451/GLPG2222 multiple dose
GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
DRUGCombined Placebo multiple dose
Combined Placebo, oral suspension, daily for 14 days
Sponsors
Galapagos NV
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Male between 18 and 50 years of age inclusive, on the date of signing the Informed Consent Form (ICF). * A body mass index (BMI) between 18-30 kg/m2, inclusive. * Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration. Clinical safety laboratory test results must be within the laboratory reference ranges or test results that are outside the reference ranges need to be considered non clinically significant in the opinion of the investigator. One retest is allowed during screening period, if deemed appropriate by the investigator. * Liver function tests must meet the following criteria: a. Aspartate aminotransferase (AST), ALT, or alkaline phosphatase (ALP) \<1.5x ULN. b. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable but no more than one subject with confirmed Gilbert's syndrome is allowed per cohort. One retest is allowed during screening period, if deemed appropriate by the investigator. * Able and willing to comply with restrictions on prior and concomitant medication as described in the protocol. * Non-smokers and non-users of any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to screening. A non-user is defined as an individual who has abstained from any nicotine containing products for at least 1 year prior to the screening. * Negative urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) and negative alcohol breath test. * No evidence of lens opacity on slit lamp examination or similar system (e.g. ITrace technology). * Agree to the use of a highly effective method of contraception (see protocol). * Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations and willing to adhere to predefined prohibitions and restrictions.
Exclusion criteria
* Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization. * Positive serology for hepatitis B virus surface antigen (HBs Ag), hepatitis C virus (HCV), or history of hepatitis from any cause with the exception of hepatitis A. * History of or a current immunosuppressive condition (e.g., human immunodeficiency virus \[HIV\] infection). * Clinically significant illness in the 3 months before the initial study drug administration. * Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula; if calculated result ≤80 mL/min, a 24-hour urine collection to determine actual value can be performed) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs. * History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence). * Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5 half-lives of the drug (whichever is the longer) before the initial study drug administration. * Active drug or alcohol abuse (more than 3 glasses of wine or beer or equivalent/day) within 2 years prior to the initial study drug administration. * Participation in a drug, drug-device combination or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug (whichever is the longer) prior to initial study drug administration. * Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change versus placebo in the proportion of subjects with adverse events | Between screening and 154 days after the last dose | To assess safety and tolerability of multiple ascending doses and combination of GLPG2451 with GLPG2222 versus placebo in healthy subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum observed plasma concentration of GLPG2451 (Cmax) given alone or in combination with GLPG2222 | Between screening and 154 days after the last dose | To characterize the pharmacokinetics of GLPG2451 and its metabolite after multiple oral doses in healthy subjects |
| Time of occurrence of Cmax for GLPG2451 given alone or in combination with GLPG2222 | Between screening and 154 days after the last dose | To characterize the pharmacokinetics of GLPG2451and its metabolite after multiple oral doses in healthy subjects |
| Area under the plasma concentration-time curve of GLPG2451 (AUC0-t) given alone or in combination with GLPG2222 | Between screening and 154 days after the last dose | To characterize the pharmacokinetics of GLPG2451 and its metabolite after multiple oral doses in healthy subjects |
| Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects | Day 1 predose and Day 14 | To explore the potential of CYP3A4 interaction with GLPG2451 |
Countries
Belgium
Outcome results
None listed